

# Tyler B Tarr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10277707/publications.pdf>

Version: 2024-02-01

9  
papers

210  
citations

1163117  
8  
h-index

1474206  
9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

238  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuromuscular Active Zone Structure and Function in Healthy and Lambert-Eaton Myasthenic Syndrome States. <i>Biomolecules</i> , 2022, 12, 740.	4.0	4
2	Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads. <i>Annals of the New York Academy of Sciences</i> , 2018, 1412, 73-81.	3.8	14
3	Transmitter release site organization can predict synaptic function at the neuromuscular junction. <i>Journal of Neurophysiology</i> , 2018, 119, 1340-1355.	1.8	17
4	Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome. <i>Molecular Neurobiology</i> , 2015, 52, 456-463.	4.0	33
5	Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K <sup>+</sup> channel blocker and a Ca <sup>2+</sup> channel agonist. <i>Journal of Physiology</i> , 2014, 592, 3687-3696.	2.9	24
6	Are unreliable release mechanisms conserved from NMJ to CNS?. <i>Trends in Neurosciences</i> , 2013, 36, 14-22.	8.6	43
7	Evaluation of a Novel Calcium Channel Agonist for Therapeutic Potential in Lambert-Eaton Myasthenic Syndrome. <i>Journal of Neuroscience</i> , 2013, 33, 10559-10567.	3.6	40
8	New calcium channel agonists as potential therapeutics in Lambert-Eaton myasthenic syndrome and other neuromuscular diseases. <i>Annals of the New York Academy of Sciences</i> , 2012, 1275, 85-91.	3.8	12
9	Synthesis and Biological Evaluation of a Selective N- and P/Q-Type Calcium Channel Agonist. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 985-990.	2.8	23